[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638250":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":10,"responsibleParty":28,"collaborators":31,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":79,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":10},{"fullName":5,"class":6},"Queen Mary University of London","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Existing PrEP user participants",null,"This group will consist of participants who already have experience with taking PrEP. They will make up 85% (n=170) of the overall recruitment target for the PrEP user participants.\n\nExisting PrEP users will have a baseline visit at M0 and the next visit will take place two months later at M2, followed by visits every two months until M12",{"label":13,"type":10,"description":14,"interventionNames":10},"New PREP-user participants","This group will consist of participants who are new to using PrEP. They will make up 15% (n=30) of the overall recruitment target for the PrEP user participants.\n\nThose who are new to using PrEP will have a baseline visit at M0 and additional visit at M1 and the next visit will take place one month later at M2, followed by visits every two months until M12",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthcare Professionals","This group will consist of 20 HCPs recruited from participating study sites.\n\nHCP participants will be asked to complete the following validated open-access questionnaires at baseline and M12:\n\n* Intervention Measure (AIM),\n* Intervention Appropriateness Measure (IAM),\n* Feasibility of Intervention Measure (FIM)\n\nThey will also be asked to complete qualitative interviews at baseline and month-12.",[19],{"name":20,"affiliation":5,"role":21},"Chloe Orkin","STUDY_CHAIR",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Nishat Halim","CONTACT","020 7377 7457","n.halim@qmul.ac.uk",{"type":29,"investigatorFullName":20,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor of Infection and Inequities",[32,35,37,39,42,44,46,48,50,52,54,56],{"name":33,"class":34},"Barts Helth NHS Trust","UNKNOWN",{"name":36,"class":6},"Guy's and St Thomas' NHS Foundation Trust",{"name":38,"class":6},"Chelsea and Westminster NHS Foundation Trust",{"name":40,"class":41},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",{"name":43,"class":6},"Sheffield Teaching Hospitals NHS Foundation Trust",{"name":45,"class":6},"University Hospital Birmingham NHS Foundation Trust",{"name":47,"class":6},"Homerton University Hospital NHS Foundation Trust",{"name":49,"class":34},"University Hospital of Wales, Cardiff",{"name":51,"class":6},"The Leeds Teaching Hospitals NHS Trust",{"name":53,"class":41},"University Hospitals Sussex NHS Foundation Trust",{"name":55,"class":6},"Barking, Havering and Redbridge University Hospitals NHS Trust",{"name":57,"class":6},"King's College Hospital NHS Trust","100638250","prep-lana-pre-exposure-prophylaxis--long-acting-novel-antiviral-agent-100638250",false,"NCT07620730","PrEP-LANA (Pre-exposure Prophylaxis- Long-acting Novel Antiviral Agent)","PrEP-LANA","Inclusion Criteria:\n\nParticipants of any gender, ethnicity or socio-economic group who meet all the following criteria are eligible for inclusion in this study:\n\n* Adults who are aged \\> 18 years at time of consent (including people of child-bearing capacity and age, non-pregnant or pregnant adults)\n* Attending a participating NHS sexual healthcare service\n* Prescribed LA CAB for PrEP according to NICE and NHS eligibility criteria (including those newly prescribed and those already using LA CAB)\n* Non-reactive \u002F negative HIV Antigen\u002FAntibody test and HIV RNA test at time of LA CAB for PrEP initiation (performed under routine care)\n* Able and willing and able to give informed consent to all study procedures prior to inclusion\n\nExclusion Criteria:\n\nPrEP user participants who meet any of the following criteria are ineligible for inclusion in this study:\n\n* One or more reactive or positive HIV test results at enrolment visit, even if HIV infection is not confirmed.\n* Currently enrolled in interventional trial of PrEP agents, HIV vaccine trial or experimental medication.\n* Plan to relocate out of the area during the study period. Note: \"Plan to relocate out of the area\" is defined as a stated intention at enrolment to move residence outside the catchment area of a participating study site during the study period, such that ongoing clinical management would likely transfer to a non-participating team.","ALL","18 Years",{"count":68,"type":69},220,"ESTIMATED","OBSERVATIONAL","The goal of this 12-month implementation science study is to generate the evidence required to ensure long-acting cabotegravir (LA CAB) as pre-exposure prophylaxis (PrEP) can be delivered in an equitable manner within the NHS. This study will recruit both PrEP users and healthcare professionals (HCPs).\n\nThe main questions it aims to answer are:\n\n* What do healthcare providers think about the feasibility of delivering LA CAB PrEP within sexual health services in the NHS?\n* How many participants stay on\u002Fremain consistent with LA CAB PrEP injections at Month 12 (PrEP persistence)?\n\nParticipants (200 PrEP users) will be followed for 12-months and asked to complete surveys at 3 study visits. A subset of 20 participants will also be asked to complete interviews about their experiences. We will also ask 20 HCPs at participating locations to complete surveys and interviews at both baseline and month 12.\n\nA core principle of equity (understanding any difference in impact on underserved populations) will be applied throughout the study. To ensure representation of a diverse group of participants that reflects the demographic groups most affected by incident HIV and most underserved by PrEP in the UK, enrolment targets will be applied and meticulously managed by the central study team, as follows:\n\n* A cap of 30% (n=60) will be applied to recruitment of White cisgender men who have sex with men who are not otherwise part of other under-represented groups (as defined below),\n* At least 70%% (n=140) of participants will represent groups currently underserved by PrEP and fall into one (or more) of the following socio-demographic categories: women (defined cisgender or transgender) OR as transgender men OR non-binary individuals OR age\\\u003C25 yrs, OR sex workers OR people who inject drugs OR racially minoritised heterosexual men.",[73,74,75,76,77,78],"PrEP","PrEP Adherence Experiences","PrEP Adherence Perspectives","PrEP Uptake","Equity","Community Setting",[73,80,63,81,82,83,77,84],"Patient and public involvement and engagement","LA CAB","Cabotegravir","Long-acting PrEP","community setting","NOT_YET_RECRUITING","2026-05-28",{"date":88,"type":89},"2026-06-02","ACTUAL",{"date":91,"type":69},"2026-10",{"date":93,"type":69},"2028-06",{"name":5,"class":6}]